Long-term hydroxyurea therapy in beta-thalassaemia patients

dc.creatorde Paula, EV
dc.creatorLima, CSP
dc.creatorArruda, VR
dc.creatorAlberto, FL
dc.creatorSaad, STO
dc.creatorCosta, FF
dc.date2003
dc.dateMAR
dc.date2014-11-16T08:11:27Z
dc.date2015-11-26T16:21:01Z
dc.date2014-11-16T08:11:27Z
dc.date2015-11-26T16:21:01Z
dc.date.accessioned2018-03-28T23:03:14Z
dc.date.available2018-03-28T23:03:14Z
dc.identifierEuropean Journal Of Haematology. Blackwell Munksgaard, v. 70, n. 3, n. 151, n. 155, 2003.
dc.identifier0902-4441
dc.identifierWOS:000181229600004
dc.identifier10.1034/j.1600-0609.2003.00037.x
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/52634
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/52634
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/52634
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1267900
dc.descriptionObjective: The study aimed to investigate the use of hydroxyurea (HU) for the treatment of beta-thalassaemia (beta -thal) patients. Methods: We examined the haematological effects of orally administered HU (10-20 mg/kg/d) in 11 patients, including four beta -thal major and seven beta -thal intermedia patients. Complete blood count and levels of foetal haemoglobin (HbF), liver enzymes and serum creatinine were evaluated before and during HU. Response to therapy was evaluated at 6 months of treatment. Results: A substantial increase in haemoglobin (Hb) level (4.1 g/dL), leading to complete withdrawal from a regular transfusion programme, was observed in one unique beta -thal major patient. In the beta -thal intermedia patients, increases in Hb level of 1.3, 1.9 and 2.0 g/dL were observed in three of seven (42.9%) patients during HU therapy. The mean values of Hb, mean corpuscular haemoglobin (MCH), and HbF were higher during HU treatment than baseline values (8.7 vs. 7.7 g/dL, P = 0.05; 26.7 vs. 22.9 pg, P = 0.05; 57.2 vs. 44.9%, P = 0.04; respectively). In contrast, the mean reticulocyte count measured during therapy decreased (97.0 x 10(9) vs. 632.0 x 10(9) /L, P = 0.03). No correlations were observed between levels of Hb and HbF (r = 0.77, P = 0.10), and levels of Hb and reticulocyte counts (r = 0.26, P = 0.31). No significant toxicity was observed in our patients. Conclusion: These results suggest that HU may improve Hb levels in beta -thal. Thus, we may conclude that a large trial concerning the response to HU in these patients should be carried out to clarify this issue.
dc.description70
dc.description3
dc.description151
dc.description155
dc.languageen
dc.publisherBlackwell Munksgaard
dc.publisherCopenhagen
dc.publisherDinamarca
dc.relationEuropean Journal Of Haematology
dc.relationEur. J. Haematol.
dc.rightsfechado
dc.sourceWeb of Science
dc.subjecthydroxyurea
dc.subjectbeta-thalassaemia
dc.subjecttherapy
dc.subjectSickle-cell Disease
dc.subjectFetal Hemoglobin-synthesis
dc.subjectThalassemia-intermedia
dc.subjectExtramedullary Hematopoiesis
dc.subjectHematological Parameters
dc.subjectSodium Phenylbutyrate
dc.subjectGlobin Synthesis
dc.subjectErythropoiesis
dc.subjectImprovement
dc.subjectExperience
dc.titleLong-term hydroxyurea therapy in beta-thalassaemia patients
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución